The company submitted three provisional patent applications with the United States Patent and Trademark Office to protect the novel combination compounds with SciSparc’s PEA Tel Aviv, Israel / Vancouver, Canada, Feb. 22, 2023 (GLOBE NEWSWIRE) — Clearmind Medicine Inc. (NASDAQ: CMND) (CSE: CMND), (FSE: CWY) (“Clearmind” or “the company”), a biotech company focused on the discovery and development…


Previous articleWebinar – Integrative Harm Reduction Psychotherapy (IHRP) Rationale, Theory and Technique
Next articleTranscend Therapeutics announces Series A funding round of $40 million